Compare GameStop Corp. (GME) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs Neurocrine Biosciences Inc — how do they compare? GameStop Corp. trades at $26.41 (market cap $12.75B), while Neurocrine Biosciences Inc trades at $142.9 (market cap $14.36B). The key difference: GameStop Corp. and Neurocrine Biosciences Inc are close in size by market cap, and GameStop Corp. is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GameStop Corp. for 61 Days and Neurocrine Biosciences Inc for 23 Days on average.
| GME | NBIX | |
|---|---|---|
Market Cap | $12.75B | $14.36B |
Volume | 13,026,993 | 1,237,180 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.53 | $185.50 |
52-Week Low | $17.87 | $123.10 |
Typical Hold Time | 61 Days | 23 Days |
Enterprise Value | $12.03B | $14.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GameStop (GME) trades at $26.37, up 7.28% in 24 hours, with a bullish technical signal and strong insider buying by CEO Ryan Cohen. The company reported net income of $131.3 million in 2025, a significant turnaround from prior losses, though revenue declined to $3.82 billion. Valuation ratios include a P/E of 16.63 and P/S of 4.22, while analyst consensus remains mixed with 16.67% buy ratings.
The outlook hinges on sustained profitability and strategic shifts, but risks include revenue volatility and competitive pressures. Insider confidence provides near-term support, yet the stock faces headwinds from cautious Wall Street sentiment and execution challenges in a declining physical retail environment.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
